HALO Halozyme
$109.72 +1.30%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
+1.30%
YTD
+66.20%
P/E
29.53
P/B
162.13
ROE
180.6%
Div yield
—
Beta
0.54
Market cap
$12.2B
RSI (14)
53
Next earnings
Nov 2, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$108.87
Close
$109.72
VWAP (n/a)
—
Day high
$111.25
Day low
$107.43
Volume
1.8M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
Yahoo Finance · Oct 1
Halozyme Announces Appointment of Jim Daly to its Board of Directors
Yahoo Finance · Sep 30
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
Yahoo Finance · Sep 23
Halozyme (HALO) Just Made A $1.3B Bet On Itself
Yahoo Finance · Sep 22
Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?
Yahoo Finance · Sep 21
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Yahoo Finance · Sep 18
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Sep 30, 2026 View → 8-K Sep 22, 2026 View → 8-K Sep 18, 2026 View → 8-K Sep 16, 2026 View → 8-K Aug 18, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell HALO. Try it in the Lab to size a position and see the risk.